RESULTS OF DAY ALIVE LEFT AND SOME RELATED ELEMENTS ON BREAST CANCER DISEASE THERE ARE ASSISTED TRIPLE-NEGATIVE BY TREATMENT REGIMEN 4AC – 4 TAXANE

Abstract

Evaluation of survival results and analysis of some additional factors related to survival in patients with stage I-IIIA breast cancer with "negative triad" supplemented with 4AC - 4Taxane. Research describes retrospective in 103 breast cancer patients with triad negative diagnoses and adjuvant treatment of 4AC-4Docetaxel regimen. Results: - TNBC is most common in the age of 50 to under 60 years old (63.1%) . There ware 57 patients  assessed Ki67 index on HMMD staining, of which mainly patients had Ki67> 20% (accounting for 73.7%). Percentage of postpartum lymph node metastasis was 32%, of which N1 (27.2%), N2 (4.8%) accounted for the majority (90.3%), phase I was only 2.9%. . The 5-year disease-free survival rate reached 89.9%, the average time was 70.6 ± 1.7 months. The overall 5-year survival rate was 90.3%, the average time was 71.4 ± 1.6 months. Recurrence rate was 8.7%, in which metastatic liver metastasis (44.4%), lung (22.2%), brain (22.2%), no recurrence and bone metastasis were encountered. he relevant survival time for the disease period was statistically significant (p <0.001), the 5-year OS rate was 100%; 96.8% and 28.6%, the difference is statistically significant (p <0.001). UTV has a negative triad that is treated complementary to 4AC-4Taxane regimen for positive results.